Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. by Till, Brian G et al.
Effect of Remission Status and Induction Chemotherapy Regimen on Outcome of 
Autologous Stem Cell Transplantation for Mantle Cell Lymphoma 
 
Short Running Title: Remission Status and ASCT outcome in MCL 
 
Brian G. Till, MD1,2 Theodore A. Gooley, PhD1,3 Nathan Crawford,1 Ajay K. Gopal, MD1,2 
David G. Maloney, MD, PhD1,2 Stephen H. Petersdorf, MD1,2 John M. Pagel, MD, PhD1,2 Leona 
Holmberg, MD, PhD1,2 William Bensinger, MD1,2 Oliver W. Press, MD, PhD1,2 
 
1Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle; 
2Department of Medicine, Division of Medical Oncology, University of Washington, Seattle; 
3Department of Biostatistics, University of Washington, Seattle 
 
Corresponding author: Brian Till, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview 
Ave N., D3-190, Seattle, WA 98109-1024; e-mail: tillb@fhcrc.org, phone 206-667-7269, fax 
206-667-1874 
 
 
 
 
Keywords: 
Mantle cell lymphoma 
Autologous stem cell transplantation 
HyperCVAD 
CHOP 
Non-Hodgkin lymphoma 
 
 
 
    
 
 
ABSTRACT 
 
We analyzed the outcomes of autologous stem cell transplantation (ASCT) following high-dose 
therapy with respect to remission status at the time of transplantation and induction regimen used 
in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received 
induction chemotherapy with HyperCVAD with or without rituximab (±R) followed by ASCT in 
first complete or partial remission (CR1/PR1), 15 received CHOP (±R) followed by ASCT in 
CR1/PR1, and 20 received ASCT following disease progression. Estimates of overall and 
progression-free survival (PFS) at three years among patients transplanted in CR1/PR1 were 
93% and 63% compared with 46% and 36% for patients transplanted with relapsed/refractory 
disease, respectively.  The hazard of mortality among patients transplanted with 
relapsed/refractory disease was 6.09 times that of patients transplanted in CR1/PR1 (P=.006).  
Patients in the CHOP (±R) group had a higher risk of failure for PFS compared to patients in the 
HyperCVAD (±R) group, though the difference did not reach statistical significance (hazard 
ratio 3.67, P=.11).  These results suggest that ASCT in CR1/PR1 leads to improved survival 
outcomes for patients with MCL compared to ASCT with relapsed/refractory disease, and a 
HyperCVAD (±R) induction regimen may be associated with an improved PFS among patients 
transplanted in CR1/PR1.
INTRODUCTION 
 
Mantle cell lymphoma (MCL) has the worst prognosis of all non-Hodgkin lymphoma (NHL) 
subtypes, with the possible exception of peripheral T cell lymphoma [1]. MCL is incurable with 
conventional therapies, with a median overall survival (OS) of 3-4 years from diagnosis in most 
series [1-3]. During the last 10 years, high-dose therapy followed by autologous stem cell 
transplantation (ASCT) has become an increasingly common treatment for MCL. Initally, ASCT 
was reserved as salvage therapy for relapsed or refractory disease, but outcomes were poor with 
this strategy [4,5]. In these studies, less heavily pre-treated patients had a longer duration of 
progression-free survival (PFS), suggesting that ASCT may lead to better outcomes if used 
earlier in the course of therapy. Subsequent trials assessed ASCT in first complete (CR1) or 
partial (PR1) remission, and although follow-up was generally short, compared to the earlier 
trials the median OS improved to approximately 5-6 years [6-12], and some studies demonstrated 
plateaus on the PFS curves, suggesting possible curability [8,9,13,14].  
 
The first prospective evidence showing a benefit for ASCT in first remission compared with 
conventional chemotherapy alone came from a trial by Dreyling et al. [15]  They reported that 
patients randomized to induction therapy with a CHOP-like regimen followed by ASCT in 
CR1/PR1 had an improved median PFS (39 mo. vs. 17 mo., P = .01) compared with patients 
who received chemotherapy followed by interferon maintenance. 
 
Anthracycline-containing induction regimens appear to lead to the best response rates and 
longest response durations for MCL [16-21], with the most commonly employed regimens being 
HyperCVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, 
alternating with cycles of high-dose methotrexate and cytarabine) with or without rituximab 
(±R), or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (±R) [20,21]. No 
randomized trials have compared these regimens, but limited retrospective data suggest that 
HyperCVAD may be superior to a CHOP-like regimen before ASCT [22,23]. We reviewed 
outcomes after ASCT at our institution with respect to remission status at the time of ASCT, as 
well as induction regimen, with particular attention to HyperCVAD (±R) vs. CHOP (±R), to 
assess differences in PFS and OS and to examine prognostic factors.   
 
PATIENTS, MATERIALS, AND METHODS 
 
Selection of Patients 
Consecutive patients with a confirmed diagnosis of MCL treated with ASCT between August 
1996 and July 2006 were included. Forty-eight of 56 patients had evidence of the (11;14) 
translocation either by polymerase chain reaction (PCR), fluorescence in situ hybridization 
(FISH), or cyclin D1 overexpression by immunohistochemistry, whereas 8 patients were 
diagnosed strictly based on histological appearance and immunophenotypic profile (CD5+, 
CD20+, CD23-) as outlined by the World Health Organization [24]. Patients were required to 
have acceptable organ function, performance status, and otherwise be deemed transplantation 
candidates by their primary oncologist. ASCT was performed at the Fred Hutchinson Cancer 
Research Center, the University of Washington Medical Center, or the Puget Sound Veterans 
Affairs Medical Center. Patients who received tandem ASCT followed by allogeneic stem cell 
transplantation were excluded from this analysis.   
 
Treatment and Monitoring 
Newly diagnosed patients were treated with induction chemotherapy with a variety of regimens, 
according to the preference of their primary oncologist. Most patients received either CHOP 
(±R) or HyperCVAD (±R) alternating with high-dose methotrexate (MTX) and cytarabine (Ara-
C). The induction regimens used in the group of patients who subsequently underwent ASCT 
with relapsed or refractory disease (Group 3 under the Statistical Analysis section) were: CHOP 
(±R) (11 patients), CVP (±R) (3 patients), fludarabine (±R) (2 patients), R-HyperCVAD (1 
patient), R-EPOCH (1 patient), antisense Bcl-2 inhibitor (1 patient), and local neck radiotherapy 
(1 patient). Some patients were referred to the transplant service for ASCT in CR1 or PR1, while 
others were referred after salvage therapy for relapsed/refractory disease. All patients underwent 
stem cell collection by apheresis after mobilization with filgrastim with or without 
chemotherapy.  Patients were then treated with high-dose therapy followed by infusion of 
cryopreserved autologous peripheral blood stem cells. The conditioning regimens used were total 
body irradiation (TBI) with cyclophosphamide and etoposide (23 patients); iodine-131-labelled 
tositumomab alone (7 patients), or in combination with cyclophosphamide and etoposide (12 
patients) or fludarabine (1 patient); and BEAM (BCNU, etoposide, cytarabine, and melphalan) or 
bulsulfan, thiotepa, and melphalan (13 patients). Stem cell products of selected patients with 
evidence of peripheral blood involvement by MCL prior to stem cell collection underwent ex 
vivo purging by immunoaffinity selection of CD34+ cells. The stem cell product of 1 patient 
underwent B-cell depletion in addition to ex vivo purging. Patients were observed for transplant-
related toxicities in the immediate post-transplant period and then referred back to their primary 
oncologists for monitoring. Twenty-five patients were treated with post-ASCT rituximab 
maintenance therapy of varying schedules. 
 
Statistical Analysis                   
Estimates of OS and PFS were obtained with the method of Kaplan and Meier and calculated 
from the time of transplant.  The probability of relapse was summarized using cumulative 
incidence estimates, where death without relapse was regarded as a competing risk.  
Comparisons of the hazard of failure for OS and PFS were made using Cox regression.  
Comparisons of primary interest involved remission status at time of ASCT, where patients were 
categorized as being transplanted either in CR1/PR1 or with relapsed or refractory disease, and 
induction regimen, where patients received either HyperCVAD (±R), CHOP (±R).  Because only 
one patient of 21 who received HyperCVAD was transplanted after relapse or progression 
compared to 11 of 26 patients who received CHOP for induction, a comparison of CHOP and 
HyperCVAD was restricted to patients transplanted in first remission.  Patients were categorized 
based on remission status and induction regimen as follows: Group 1: HyperCVAD (±R) 
followed by ASCT in CR1/PR1; Group 2: CHOP (±R) followed by ASCT in CR1/PR1; and 
Group 3: ASCT with relapsed or refractory disease.  Three patients in the CHOP group received 
an additional chemotherapy regimen in PR1 in an unsuccessful attempt to achieve a CR and were 
considered to be in PR1 at ASCT. A fourth patient in the CHOP group achieved a CR after 2 
additional cycles of chemotherapy (R-HyperCVAD) in PR1 and was considered to be a CHOP 
patient in CR1 at ASCT. Groups 1 and 2 were then combined to analyze the differences between 
patients who underwent ASCT in CR1/PR1 and patients who underwent ASCT with relapsed or 
refractory disease (Group 3), and the impact of CHOP vs. HyperCVAD among patients 
transplanted in CR1/PR1 was assessed by comparing Groups 1 and 2. 
 
Responses were determined according to the International Working Group criteria [25]. The pre-
treatment serum lactate dehydrogenase (LDH) values of several patients who underwent 
induction therapy at other institutions were not available. For these patients, the International 
Prognostic Index (IPI) scores were calculated assuming a normal LDH value; thus, the IPI scores 
may be underestimated for those patients.  
 
Factors other than remission status at ASCT and induction regimen were assessed for their 
association with outcome.  These factors included age at diagnosis, sex, stage at diagnosis, serum 
LDH at diagnosis, performance status at diagnosis, IPI score, presence of bone marrow or 
gastrointestinal tract involvement, presence of splenomegaly, number of extranodal sites of 
disease, presence of B symptoms, serum hemoglobin (Hb) at diagnosis, number of cycles of 
induction chemotherapy, use of rituximab with induction, number of pre-ASCT chemotherapy 
regimens (not counting mobilization), response to induction therapy, preparatory regimen for 
ASCT, and post-ASCT rituximab therapy. The impact of using rituximab after ASCT was 
assessed by considering rituximab use as a time-dependent covariate, with the covariate 
assuming a value of 0 until the time of first administration of rituximab following ASCT, at 
which time the covariate assumes the value 1. The relatively small number of events limited the 
number of factors that could be included in a multivariate model to two.  All two-sided p-values 
from regression models were calculated using the Wald test. 
 
Institutional Approval  
Institutional approval from the Fred Hutchinson Cancer Research Center was obtained to 
evaluate patients’ medical records retrospectively. Patients were either enrolled into 
institutionally approved studies or treated with standard transplantation protocols.  
 
RESULTS 
 Patients  
Fifty-six consecutive patients (median age at diagnosis 54.5, range 35-70) were treated with 
high-dose therapy followed by ASCT at our center between August 1996 and July 2006, with a 
median follow-up time among survivors of 24.6 months and maximum follow-up time of 10.1 
years. Patient characteristics are listed in Table I.  All patients had pathologically confirmed 
MCL, with 48 of 56 patients having either positive cyclin D1 by immunohistochemistry or 
evidence of t(11;14) by FISH or PCR. All patients but 1 (98%) had stage III-IV disease, and 77% 
of patients were male.  
 
Baseline characteristics were similar among the primary comparison groups, with a few 
exceptions.  A higher percentage of patients treated with CHOP (±R) followed by ASCT in 
CR1/PR1 had B symptoms (67%) than patients treated with HyperCVAD (±R) followed by 
ASCT in CR1/PR1 (38%) or patients with relapsed/refractory disease at the time of ASCT 
(25%). A slightly higher percentage of patients in the CHOP group had a performance status of 2 
or greater compared with patients in the HyperCVAD group (13% and 0%, respectively).  More 
patients with relapsed/refractory disease at ASCT had an IPI score at diagnosis of 2 or greater 
than patients transplanted in first remission (75% and 50%, respectively).  
  
Response to Induction 
With respect to the 3 comparison groups, 21 patients were treated with a HyperCVAD (±R) 
regimen followed by ASCT in CR1/PR1, 15 patients were treated with CHOP (±R) followed by 
ASCT in CR1/PR1, and 20 patients underwent ASCT with relapsed/refractory disease (Table I). 
Among the 21 patients in the HyperCVAD group, 17 (81%) had a complete response or 
complete response unconfirmed (CR/CRu) to induction, compared with only 4 of 15 patients 
(27%) in the CHOP group (P = .002). Among patients who underwent ASCT after relapse, 15 
(75%) had a response to initial induction therapy (7 CR/CRu, 8 PR), 3 patients had stable 
disease, and 2 had progressive disease (Table II). Fifteen of the 20 patients had chemosensitive 
disease at ASCT, as defined by cumulative response (CR or PR) since the time of last 
relapse/progression. All 5 of the primary refractory patients subsequently responded to salvage 
chemotherapy regimens. Patients were more likely to receive a CHOP (±R) regimen in the early 
years of the study and more likely to receive HyperCVAD (±R) in more recent years. The 
median follow-up of survivors in the CHOP group was 31 months, and the median follow-up for 
survivors in the HyperCVAD group was 14 months. This difference was due primarily to the 
three long-term survivors in the CHOP group; the number of patients with follow-up less than 3 
years was more similar between the two groups: 13/20 (65%) of the HyperCVAD patients and 
7/13 (54%) of the CHOP patients.  There is only one death beyond 3 years (at 3.6 years in CHOP 
group). 
 
Outcomes After Stem Cell Transplantation 
At most recent follow-up, 13 patients had died, 12 of progressive disease, and 1 patient, in the 
relapsed/refractory group, from refractory cytopenias leading to a fatal infection (1.8% 
transplant-related mortality). There were 19 relapses, 12 of which led to death. The median OS 
of the entire group was not yet reached, and the median PFS was 4.0 years, with estimated 3-year 
OS and PFS of 72% and 52%, respectively (Figure 1). 
 
Patients who underwent ASCT in CR1/PR1 had an estimated 3-year OS of 93% compared to 
46% for patients who were transplanted with relapsed/refractory disease (Figure 2).  PFS at 3 
years was estimated to be 63% and 35%, respectively, in these 2 groups of patients.  Risk of 
mortality and risk of PFS failure were increased among patients undergoing ASCT with 
relapsed/refractory disease compared to patients transplanted in CR1/PR1 (HR 6.09 [95% CI 
1.66-22.30], P = .006, and HR 3.15 [1.28-7.71], P = .01, respectively). 
 
Given the low number of deaths among patients transplanted in CR1/PR1 (2 in the CHOP group 
and 1 in the HyperCVAD group), a statistical comparison of mortality between these 2 induction 
regimens is not meaningful. Among patients treated with HyperCVAD (±R) followed by ASCT 
in first remission, the median OS and PFS have not been reached. Among patients treated with 
CHOP (±R) followed by ASCT in CR1/PR1, the median OS was not yet reached, and the median 
PFS was 33.2 months. The estimated 3-year PFS was 81% for patients in the HyperCVAD group 
and 44% for patients in the CHOP group (Figure 3). The hazard of failure for PFS among CHOP 
(±R) patients transplanted in CR1/PR1 was 3.67 (95% CI 0.77-18.24) times that of patients in the 
HyperCVAD group, but this difference did not reach statistical significance (P = .11). 
 
One patient in the relapsed/refractory group developed a melanoma 5 years after ASCT. 
Excluding non-melanoma skin malignancies, no other secondary malignancies were reported 
among the study patients after ASCT. 
 
Prognostic Factors Other than Induction Regimen and Remission Status at Transplant  
A number of factors other than induction regimen and remission status at transplant were 
examined for their association with overall mortality and failure for PFS (Table III).  Because of 
the limited number of events (13 deaths, 20 deaths or relapses), the number of factors that could 
be included in any regression model is limited. In univariate models for overall mortality, 
elevated LDH was associated with an increased risk of death (44%, compared to 0%, P = .0002).  
Patients with an IPI of 0-1 were less likely to die compared to patients with higher IPI scores 
(9% of patients with IPI of 0-1, compared to 33% with higher IPI, HR 0.23 [0.05-1.03], P = .05), 
and patients whose induction regimen contained rituximab were also less likely to die compared 
to those whose regimen did not contain rituximab (15% compared to 47%, HR 0.33 [0.11-1.00], 
P = .05).  Similarly, patients who received rituximab after transplantation had a reduced hazard 
ratio for mortality (0.13 [0.02-1.03], P = .05). No other factors were statistically significantly 
associated with mortality.  After adjusting for IPI score (0-1 vs. 2-5), the hazard of mortality 
among patients transplanted with relapsed/refractory disease remained statistically significantly 
higher than among patients transplanted in first remission, although the magnitude of the 
difference was reduced (HR 5.12, P = .02).  A similar finding held after adjusting for use of 
rituximab in the induction regimen (HR 5.13, P = .02).  Adjusting for conditioning regimen 
(modeled as TBI-containing vs. I-131-containing vs. high-dose chemotherapy only) likewise did 
not reduce the association of ASCT in first remission with improved survival (HR 13.37, P = 
.005), and adjusting for the use of rituximab following ASCT led to the same qualitative 
conclusion with respect to ASCT in first remission (HR 4.62, P = .03). 
 
The same factors listed above associated with mortality were associated with PFS (Table IV).  
Additionally, a better response to induction was associated with improved PFS; patients 
achieving a PR as opposed to a CR had a hazard ratio (HR) of 5.88 for relapse or mortality (1.67-
20.67, P = .006), and patients that did not achieve either a CR or PR had a HR of 16.43 (3.51-
76.84, P = .0004). Adjusting for IPI or use of rituximab during induction did not change the 
conclusion with respect to the association seen between remission status at ASCT and PFS, 
although the magnitude of the association was reduced (HR 2.73, P = .03 after adjusting for IPI; 
HR 2.62, P = .04 after adjusting for rituximab).  The association fell below the level of statistical 
significance after adjusting for conditioning regimen (HR 2.46, P = .08), as it did after separately 
adjusting for rituximab use following ASCT (HR 2.30, P = .10). No other factors examined were 
statistically significantly associated with the risk of relapse/mortality.   
 
 
 
DISCUSSION 
 
Historically, the use of ASCT in patients with MCL began as a salvage therapy for relapsed or 
refractory disease, although it later became clear that survival results were poor with this 
approach [4,5,26]. Several studies subsequently emerged suggesting improved clinical outcomes 
for patients transplanted in first remission compared with historical controls or patients receiving 
delayed transplants [8,27-29]. This evidence was supported by a prospective trial showing 
improved PFS for patients randomized to ASCT rather than interferon maintenance following 
induction chemotherapy [15]. Based on these data, and encouraged by technical advances in the 
management of complications related to stem cell transplantation, ASCT as consolidation 
therapy in first remission has become the preferred treatment for MCL for many oncologists and 
hematologists, although this practice remains controversial. 
 
In this study we evaluated outcomes of patients with MCL after ASCT with respect to their 
remission status at the time of transplant and the induction regimen they received. We found that 
patients who underwent ASCT in first remission had significantly better OS and PFS after ASCT 
compared to patients who had relapsed/refractory disease at ASCT.  Although more patients with 
relapsed/refractory disease had an IPI score greater than 2 compared with patients in CR1/PR1 at 
ASCT, this did not appear to account for the observed difference between the groups, as a 
multivariable analysis adjusting for IPI continued to show an OS and PFS benefit for the patients 
transplanted in first remission. The OS benefit also remained significant after adjusting for 
conditioning regimen, although the PFS benefit was reduced. We also found that patients 
achieving less than a CR with induction therapy had a significantly higher risk of mortality 
compared with patients who achieved a CR.  
 
These results, along with studies demonstrating better outcomes among patients transplanted in 
CR1 as opposed to PR1 [23,27], highlight the importance of optimizing the initial response to 
chemotherapy and remission status at ASCT. It is important to emphasize that the current data do 
not, and cannot, address the question of whether ASCT is preferred over not being transplanted, 
as only patients who proceeded to ASCT are currently considered.   
 
Recent years have seen a shift in the most commonly employed induction regimens for 
previously untreated MCL as data on newer regimens have emerged. More intensive regimens 
such as a HyperCVAD/MTX-Ara-C regimen, in combination with rituximab, are increasingly 
being used in favor of older regimens such as R-CHOP and R-CVP, although the optimal 
induction regimen has not yet been firmly established. One series by Conde et al. compared post-
ASCT outcomes of patients from an international database with respect to induction regimen, 
and found a 4-year disease-free survival of 68% for patients treated with HyperCVAD compared 
with 33% for patients treated with a CHOP-like regimen [22]. In a more recent abstract by Vose 
et al. of 80 patients who underwent ASCT in CR1/PR1, patients who were treated with a 
HyperCVAD (±R) induction regimen had a significantly better 3-year OS (97% vs. 68%) than 
patients who were treated with a CHOP-like (±R) induction regimen [23]. Additionally, a subset 
analysis of a study by Ganti et al. suggested that a HyperCVAD (±R) induction regimen was 
associated with fewer relapses [30].  
 
In this study we compared the outcomes of patients treated with ASCT in CR1/PR1 after 
receiving either a HyperCVAD/MTX-Ara-C (±R) or CHOP (±R) induction regimen. A statistical 
comparison of these 2 groups with respect to OS is difficult, since there were only 3 deaths 
among patients transplanted in first remission (2 in the CHOP group and 1 in the HyperCVAD 
group).  With regard to PFS, however, there was a higher risk of failure among patients in the 
CHOP (±R) group, primarily through a higher risk of relapse, compared to those treated with 
HyperCVAD (±R).  The difference did not reach statistical significance, but the power to detect 
such a difference was limited by the small number of events. That the estimated 3-year OS and 
PFS of patients in this group were very similar to those reported by Vose et al., however, 
increases one’s confidence that this PFS trend reflects a true superiority of HyperCVAD (±R) in 
MCL. Furthermore, there was a significantly better CR/CRu rate among patients in the 
HyperCVAD group compared with those in the CHOP group (81% vs. 27%). As with any 
retrospective study, however, there were limitations. For example, more patients in the CHOP 
group had high-risk disease based on IPI score, and fewer patients received rituximab as part of 
induction compared with patients in the HyperCVAD group, which may have contributed to their 
lower CR rate with induction and PFS. We must also acknowledge that the median follow-up of 
patients in the CHOP group is longer than patients in the HyperCVAD group, and that it is 
possible that this difference might have influenced our findings. The above differences mainly 
reflect changes in treatment preference over time; in the earlier years of the study, more patients 
received a CHOP (±R) induction regimen, with fewer patients receiving rituximab, whereas in 
more recent years, patients were more frequently treated with a HyperCVAD induction regimen 
that included rituximab.  
 
Although HyperCVAD appears to be associated with higher toxicity than CHOP [16,20,21] and 
requires hospitalization for infusion, it was not associated with a higher rate of mortality during 
subsequent transplantation. Only one patient died without a preceding relapse (1.8% non-relapse 
mortality). It should be noted, however, that patients who died during induction or were 
otherwise not able to tolerate ASCT were not included in this study. The incidence of secondary 
malignancies was 1 of 56 (1.8%), though a longer follow-up time will be needed to address this 
concern adequately. 
 
An unresolved question concerning MCL is whether ASCT is curative. Previous series present 
conflicting results, with some studies showing apparent plateaus on PFS curves, whereas others 
do not [6-11,13-15,28,31-33].   Nevertheless, it is clear that many patients achieve long-term 
disease-free intervals following ASCT in first remission. One patient on this study remains in a 
molecular CR more than 10 years after ASCT, and is likely cured. Further studies are needed to 
identify pre-treatment characteristics predictive of long-term survival with induction plus ASCT 
or intensive induction alone.  
 
In conclusion, the results of this study suggest that treating MCL patients with ASCT in first 
remission affords a survival benefit when compared to ASCT after relapse or progression. Our 
data also show that among patients who are transplanted in CR1/PR1, those who receive 
HyperCVAD (±R) followed by ASCT may have improved PFS compared to those treated with 
CHOP (±R) followed by ASCT.  In view of the higher toxicity and need for hospitalization 
associated with the HyperCVAD regimen, randomized trials to confirm these results are 
warranted. 
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Table I. Patient characteristics 
Parameter  All 
patients 
n (%) 
HyperCVAD (±R)  
+ ASCT in 
CR1/PR1 
n (%) 
CHOP (±R)   
 + ASCT in 
CR1/PR1 
n (%) 
ASCT with 
relapsed/refractory 
disease  
n (%) 
Total no. 56 21 15 20 
Sex     
   Male 43 (77) 17 (81) 11 (73) 15 (75) 
   Female 13 (23) 4 (19) 4 (27) 5 (25) 
Age, y, median 54.5 53 56 57.5 
   Range 35-70 41-69 35-70 45-68 
Ann Arbor stage     
   I-II 1 (2) 0 (0) 0 (0) 1 (5) 
   III-IV 55 (98) 21 (100) 15 (100) 19 (95) 
Presence of B symptoms   23 (41) 8 (38) 10 (67) 5 (25) 
LDH at diagnosis     
   Normal 26 (46) 14 (67) 6 (40) 6 (30) 
   Abnormal 16 (29) 4 (19) 5 (33) 7 (35) 
   Unknown 14 (25) 3 (14) 4 (27) 7 (35) 
IPI     
   0-1 23 (41) 11 (52) 7 (47) 5 (25) 
   2-3 30 (54) 10 (48) 5 (33) 15 (75) 
   4-5 3 (5) 0 (0) 3 (20) 0 (0) 
ECOG performance status     
   0-1 53 (95) 21 (100) 13 (87) 19 (95) 
   2-3 3 (5) 0 (0) 2 (13) 1 (5) 
   4-5 0 (0) 0 (0) 0 (0) 0 (0) 
Table I (Continued) 
*A bone marrow biopsy was not performed at diagnosis for 2 patients in this group. 
†One patient also received IL-2 in addition to high-dose chemotherapy.  
Median no. of extranodal sites, 
exclusive of spleen 
1 1 1 1 
Serum hemoglobin (Hb) at diagnosis     
   Hb ≥12 30 (54) 13 (62) 8 (54) 9 (45) 
   Hb <12 17 (30) 7 (33) 5 (33) 5 (25) 
   Unknown 9 (16) 1 (5) 2 (13) 6 (30) 
Rituximab used with induction 
therapy 
41 (73) 20 (95) 11 (73) 10 (50) 
Treatment with 3 or more prior 
regimens 
0 (0) 0 (0) 0 (0) 12 (60) 
Purged (CD34+ selected) stem cell 
product 
12 (21) 0 (0) 5 (33) 7 (35) 
ASCT conditioning      
   TBI-containing regimen 23 (41) 16 (76) 5 (33) 2 (10) 
   I-131-labeled anti CD20 Ab-
containing regimen 
20 (36) 2 (10) 5 (33) 13 (65) 
   High-dose chemotherapy only 13 (23) 3 (14) 5 (33) 5 (25)† 
Use of post-ASCT rituximab 
maintenance therapy 
    
   Yes 25 (45) 14 (67) 7 (47) 4 (20) 
   No 27 (48) 5 (24) 7 (47) 15 (75) 
   Unknown 4 (7) 2 (9) 1 (6) 1 (5) 
Table II. Response to induction therapy and remission status at ASCT 
Parameter All patients 
n (%) 
HyperCVAD (±R)  
+ ASCT in 
CR1/PR1 
n (%) 
CHOP (±R)   
 + ASCT in 
CR1/PR1 
n (%) 
ASCT with 
relapsed/refractory 
disease  
n (%) 
Response to induction therapy     
   CR/CRu 28 (50) 17 (81) 4 (27) 7 (35) 
   PR 23 (41) 4 (19) 11 (73) 8 (40) 
   Other 5 (9) 0 (0) 0 (0) 5 (25) 
Remission status at ASCT     
   CR1/CRu1 23 (41) 18 (86)* 5† (33) 0 (0) 
   PR1 13 (23) 3 (14) 10 (67) 0 (0) 
   Other 20 (36) 0 (0) 0 (0) 20 (100) 
* One patient converted from a PR to a CR with chemomobilization prior to stem cell collection. 
† One patient converted from a PR to a CR after receiving 2 cycles of R-HyperCVAD after the initial R-CHOP x 4 
cycles 
 
 
 
 
 
 
 
 
 
 
 
Table III. Univariate regression analysis results for overall mortality 
Factor Hazard Ratio 95% CI p-value 
Age* Older, more failure ---  .65 
Age < 60 
Age ≥ 60 
1 
1.11 
---  
0.34-3.64 
---  
.87 
Stage III† 
Stage IV 
1 
1.42 
---  
0.18-10.94 
---  
.74 
PS 0-1 
PS 2-3 
1 
1.99 
---  
0.26-15.45 
---  
.51 
Normal LDH‡ 
High LDH 
1 
Infinite 
---  ---  
.0005 
ENS 0-1 
ENS 2-3 
1 
2.02 
---  
0.60-6.78 
---  
.26 
No B Symptoms 
B Symptoms 
1 
1.96 
---  
0.66-5.85 
---  
.23 
IPI 0-1 
IPI 2-3 
IPI 4-5 
1 
4.83 
0 
---  
1.07-21.85 
--- 
---  
.04 
.23 
Female 
Male 
1 
1.50 
---  
0.33-6.77 
---  
.60 
 *Age, number of cycles, and number of pre-ASCT chemo regimens modeled as a continuous linear variable 
†No patients with Stage II disease, only 1 patient with Stage I disease 
No Splenomegaly 
Splenomegaly 
1 
3.06 
---  
0.84-11.14 
---  
.09 
No BM Involvement  
BM Involvement  
1 
0.92 
---  
0.20-4.19 
---  
.92 
No GI Involvement 
GI Involvement 
1 
1.24 
---  
0.34-4.53 
---  
.75 
Hb < 12 
Hb ≥ 12 
1 
0.49 
---  
0.15-1.60 
---  
.23 
Number of Cycles of Induction Chemo* Higher, less failure ---  .15 
No Rituximab in Induction 
Rituximab in Induction 
1 
0.33 
---  
0.11-1.00 
---  
.05 
0-1 pre-ASCT Chemo 
≥2 Chemo 
1 
8.38 
--- 
1.85-37.96 
---  
.006 
CR to Induction  
No CR to Induction 
1 
5.65 
---  
1.25-25.64 
---  
.02 
CR1 at ASCT 
PR1 at ASCT 
Neither CR1 nor PR1 at ASCT 
1 
2.93 
10.85 
---  
0.27-32.41 
1.38-85.11 
---  
.38 
.02 
No Post-ASCT Rituximab 
Post-ASCT Rituximab 
1 
0.13   
--- 
0.02-1.03 
--- 
.05 
Group 1 (HyperCVAD ) 
Group 2 (CHOP) 
Group 3 (relapsed/refractory) 
1 
2.28 
9.76 
--- 
0.21-25.26 
1.24-76.98 
--- 
.50 
.03 
‡Fourteen patients missing data, 6 (43%) have died 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IV. Univariate regression analysis results for failure for PFS 
Factor Hazard Ratio 95% CI p-value 
Age* Older, more failure ---  .25 
Age < 60 
Age ≥ 60 
1 
1.91 
---  
0.77-4.70 
---  
.16 
Stage III† 
Stage IV 
1 
0.47 
---  
0.13-1.63 
---  
.23 
PS 0-1 
PS 2-3 
1 
4.52 
---  
0.99-20.66 
---  
.05 
Normal LDH‡ 
High LDH 
1 
7.41 
---  
1.97-27.80 
---  
.003 
ENS 0-1 
ENS 2-3 
1 
1.96 
---  
0.66-5.77 
---  
.22 
No B Symptoms 
B Symptoms 
1 
2.21 
---  
0.90-5.40 
---  
.08 
IPI 0-1 
IPI 2-3 
IPI 4-5 
1 
5.74 
5.20 
---  
1.65-19.91 
0.51-52.97 
---  
.006 
.16 
Female 
Male 
1 
1.21 
---  
0.27-5.18 
---  
.81 
No Splenomegaly 
Splenomegaly 
1 
2.46 
---  
0.94-6.44 
---  
.07 
 *Age, number of cycles, and number of pre-ASCT chemo regimens modeled as a continuous linear variable 
†No patients with Stage II disease, only one patient with Stage I disease 
‡Fourteen patients missing data, 8 (57%) have died and/or relapsed 
No BM Involvement 
BM Involvement 
1 
0.80 
---  
0.23-2.78 
---  
.72 
No GI Involvement 
GI Involvement 
1 
1.23 
---  
0.40-3.77 
---  
.72 
Hb < 12 
Hb ≥ 12 
1 
0.47 
---  
0.18-1.23 
---  
.12 
Number of Cycles of Induction Chemo* Higher, less failure ---  .64 
No Rituximab in Induction 
Rituximab in Induction 
1 
0.28 
---  
0.12-0.69 
---  
.005 
0-1 pre-ASCT Chemo 
≥2 Chemo 
1 
4.04 
---  
1.55-10.53 
---  
.004 
CR to Induction  
PR to Induction 
Neither CR nor PR 
1 
5.88 
16.43 
---  
1.67-20.67 
3.51-76.84 
---  
.006 
.0004 
CR1 at ASCT 
PR1 at ASCT 
Neither CR1 nor PR1 at ASCT 
1 
4.69 
7.66 
---  
0.94-23.32 
1.71-34.29 
---  
.06 
.008 
No Post-ASCT Rituximab 
Post-ASCT Rituximab 
1 
0.21 
--- 
0.05-0.90 
--- 
.04 
Group 1 (HyperCVAD ) 
Group 2 (CHOP) 
Group 3 (relapsed/refractory) 
1 
3.67 
6.93 
--- 
0.74-18.20 
1.55-31.00 
--- 
.11 
.01 
 FIGURE LEGENDS 
 
 
Figure 1. Kaplan-Meier estimates of overall survival, progression free-survival, and relapse for 
the entire cohort. The probability of survival, progression-free survival, and relapse at 3 years 
were 72%, 52%, and 45%, respectively.  
 
 Figure 2. Kaplan-Meier estimates of overall survival from the time of ASCT, with respect to 
remission status at ASCT. The estimated 3-year survival for patients treated with ASCT in 
CR1/PR1 was 93%, compared with 46% in patients who underwent ASCT with relapsed or 
refractory disease.  
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Figure 3. Kaplan-Meier estimates of overall survival (A) and progression-free survival (B) from 
the time of ASCT, with respect to primary comparison group. The estimated 3 year OS and PFS 
for patients treated with HyperCVAD (±R) followed by ASCT in CR1/PR1 were 94% and 81%, 
respectively, compared with 92% and 44%, in patients treated with a CHOP (±R) regimen 
followed by ASCT in CR1/PR1. Patients who received a different induction regimen or 
underwent ASCT with refractory disease or after relapse had the lowest OS and PFS at 46% and 
36%. 
 
 
 
 
